Health and well-being in communities
To improve access and support people in vulnerable communities, we make targeted product and financial donations to programmes run by local and global partners that are designed to be sustainable in the long term.
We also encourage our employees to volunteer their time and expertise. In 2016, we invested £210 million in communities around the world.
Discover more about our programmes
Our philosophy is to target support on selected health and educational programmes that are innovative, sustainable and produce tangible results. The programmes we support share our vision of enhancing healthcare, and where possible they offer opportunities to involve GSK employees in assisting communities where we do business. We are working across the world with local charities to improve healthcare and education outcomes in those countries.
Partnering to save one million children’s lives
Through our partnership with Save the Children we are combining our capabilities in R&D, supply chain, procurement and vaccines with the charity’s expertise working with the most vulnerable children. Together we are delivering tangible results. To date, we have reached over 2.6 million children. Over 97,600 under-fives have been fully immunised, over 290,000 children have been vaccinated against measles or polio, over 187,800 children have been treated for diarrhoea, malaria or pneumonia, and over one million children have been screened for malnutrition.
Using insights and on-the-ground knowledge from Save the Children, we have been working to reformulate the antiseptic chlorhexidine solution used in GSK’s Corsodyl mouthwash into a gel to prevent umbilical cord infections. This issue is exacerbated in developing countries, where many births take place at home and without proper health care.
The transformation of an everyday antiseptic into a medicine, with the aim of saving newborns in the world’s poorest countries, is a key milestone in the GSK and Save the Children Partnership. Together, we have developed a gel which is a reformulation of chlorhexidine, an antiseptic used in a GSK mouthwash, for the prevention of umbilical cord infections that could lead to neonatal sepsis.
Combining GSK’s science, regulatory and manufacturing expertise with Save the Children’s insights and expertise in reaching marginalised children and families, the gel has been specifically designed for remote communities. It is heat-stable, to endure long hot journeys without the need for refrigeration, and is in single-use tear-open sachets so it can be easily administered by health workers and mothers in the communities who need it most.
The chlorhexidine gel has been registered successfully in four countries so far – Kenya, Tanzania, Liberia and DRC. GSK is offering it at a not-for-profit price, and sharing its manufacturing knowledge to enable local companies to make the product themselves. By April 2017 over 17,000 newborns in Bungoma County, Kenya have benefitted from the chlorhexidine gel and mothers and healthworkers have been overwhelmingly positive about it.
Every year millions of people are displaced by disasters and emergency situations. These crises can devastate families, leaving them without access to adequate food, shelter or healthcare. GSK works with partners and humanitarian organisations to prepare for and respond to emergency situations. In some instances, we fast-track the development of life-saving vaccines, and in others, we contribute by donating cash, products and our employees’ time. We also invest in long-term rebuilding and reconstruction in the aftermath of a disaster.
Since 2012 we have provided £2.1 million in cash and product donations to support refugees.
We donated medicines valued at £127 million in 2016. This support includes our Patient Assistance Programmes, over 900 million albendazole tablets to fight lymphatic filariasis and soil-transmitted helminths and product donations to support humanitarian aid, distributed through our partners AmeriCares, Direct Relief, IMA World Health, MAP International and Project HOPE.
Rewarding innovation in healthcare
In February 2017, we announced the winners of the fourth annual $1 million Healthcare Innovation Award, set up by GSK and Save the Children to reward sustainable and scalable healthcare innovations that have resulted in tangible improvements to under-five child survival rates. The 2017 winners include innovations in strengthening health systems, community programmes and treatment strategies from around the globe.
Health and well-being features
Giving mothers and babies a healthier start
Find out how our scientists have adapted an ingredient from a GSK mouthwash into a potentially life-saving gel for newborns in developing countries
A new response to humanitarian crises
Humanitarian crises are becoming more frequent, more widespread and more complex. It’s clear that a new approach is needed.
Reinvesting in healthcare
We have committed to reinvest 20% of our profits back in to improving the healthcare infrastructure in the world’s Least Developed Countries
Health for all
Our part in tackling global health challenges and our aim to extend the benefits of our products to more people
We are changing the way we work to further embed our values in everything we do, including the way we research, develop, sell and market our products
Learn how we create an inspiring and supportive work environment that encourages employees to develop capabilities and achieve their best